630-576-9696 Menu
Meyers & Flowers Trial Attorneys

No Fee Unless We Win!

630-576-9696

English / Español

Nationwide / Available 24/7

Categories

Personal Injury Harmful Products Dangerous Drugs Pressure Cookers Defective Hip Litigation Class Action Mass Tort Record Settlements and Verdicts Publications Firm Features Medical Malpractice Client Results Meyers and Flowers News Client Resources Recalls and Warnings Baby Products FAQ Ted A Meyers Peter J Flowers Craig D Brown Jonathan P Mincieli James A McPhedran Lauren E Edmunds Michael W Lenert Frank V Cesarone Thomas M Connelly Christopher J Warmbold

Oxbryta® Recall: Pfizer Pulls Sickle Cell Medication Due to Severe Side Effects

09/27/2024

Pfizer has issued a global recall of Oxbryta, a drug approved for the treatment of sickle cell disease (SCD). Oxbryta, which aimed to improve oxygen transport in red blood cells, offered hope to many individuals suffering from this debilitating condition. However, recent findings have revealed that the drug may pose serious life-threatening risks that outweigh its potential benefits, leading to th...

View More

INVESTIGATING THE DANGEROUS LINK BETWEEN KRATOM USE AND HEALTH RISKS

11/21/2023

Kratom, an herbal supplement, has gained popularity in recent years for its alleged therapeutic effects. However, as its usage has surged, so has concern about the potential dangers associated with it. The experienced personal injury attorneys at Meyers & Flowers are investigating Kratom. This controversial herbal remedy has been linked to a series of alleged injuries and deaths and may pose a...

View More

FDA Amends Label on Harmful Prescription Eye Injection

07/07/2022

Beovu After initial approval in 2019, the U.S. Food and Drug Association released an amended label on the prescription injection drug Beovu to disclose the severe side effects it may cause. Released by the medical research center Novartis, Beovu is one of three drugs approved by the FDA that treats Wet AMD, a chronic eye disease. Since its release, Beovu has been found to have some extremely serio...

View More

FDA Pulls Cancer Drug Approvals Due to Safety Concerns

06/08/2022

FDA Pulls Cancer Drug Approvals Due to Safety Concerns Safety concerns have prompted the FDA to withdraw approval of umbralisib (Ukoniq) On June 1, 2022, the U.S. Food and Drug Administration withdrew its approval for the cancer medicine umbralisib (Ukoniq) permitted for the treatment of adults with marginal zone lymphoma (MZL) and follicular lymphoma (FL), the agency announced in a safety commun...

View More

Schedule a free case evaluation or join a case

Contact Us

© Meyers & Flowers Trial Attorneys. All Rights Reserved. Web Design & Internet Marketing by Studio III

Privacy Policy

Sitemap

Contact Us